Supernus Pharmaceuticals (SUPN) Total Liabilities (2011 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly Total Liabilities of $396.9 million for Q2 2026, up 24.61% year-over-year from $318.5 million in Q2 2025, and down 6.38% on a QoQ basis from $423.9 million in Q1 2026.
Supernus Pharmaceuticals (SUPN) Total Liabilities (2011 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported Total Liabilities for 16 years, with the latest figure at $396.9 million in Q2 2026.
- Total Liabilities for Q2 2026 came in at $396.9 million, up 24.61% year-over-year; the trailing twelve-month figure through Jun 2026 was $396.9 million (up 24.61% YoY), and the FY2025 annual result was $390.9 million, up 17.63% from the prior year.
- Total Liabilities fell to $396.9 million in Q2 2026, from $423.9 million in the prior quarter.
- Over five years, Total Liabilities peaked at $879.7 million in Q1 2023 and troughed at $316.6 million in Q1 2025.
- A 5-year average of $495.6 million and a median of $374.1 million in 2023 frame the typical range for Total Liabilities.
- The widest annual swing landed in 2024, when Total Liabilities plunged 57.38%; it then jumped 33.9% in 2026.
- A 5-year view of Total Liabilities shows it stood at $816.3 million in 2022, then tumbled by 56.37% to $356.2 million in 2023, then slipped by 6.69% to $332.3 million in 2024, then climbed by 17.63% to $390.9 million in 2025, then advanced by 1.52% to $396.9 million in 2026.
- Per Business Quant data, the three most recent Total Liabilities figures were $396.9 million in Q2 2026, $423.9 million in Q1 2026, and $390.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | -21.66 Bn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | 32.10 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | 11.93 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 50.85 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 819.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 20.78 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 1.67 Bn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 6.97 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 2.12 Bn |
| 10 | Supernus Pharmaceuticals | 2.75 Bn | 2.37 Bn | 185.39 Mn | 396.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 396.88 Mn |
| Mar 31, 2026 | 423.92 Mn |
| Dec 31, 2025 | 390.93 Mn |
| Sep 30, 2025 | 370.09 Mn |
| Jun 30, 2025 | 318.51 Mn |
| Mar 31, 2025 | 316.59 Mn |
| Dec 31, 2024 | 332.34 Mn |
| Sep 30, 2024 | 335.55 Mn |
| Jun 30, 2024 | 358.38 Mn |
| Mar 31, 2024 | 374.92 Mn |
| Dec 31, 2023 | 356.16 Mn |
| Sep 30, 2023 | 372.97 Mn |
| Jun 30, 2023 | 373.19 Mn |
| Mar 31, 2023 | 879.66 Mn |
| Dec 31, 2022 | 816.30 Mn |
| Sep 30, 2022 | 840.33 Mn |
| Jun 30, 2022 | 853.54 Mn |
| Mar 31, 2022 | 811.07 Mn |
| Dec 31, 2021 | 873.30 Mn |
| Sep 30, 2021 | 744.57 Mn |